Selection of human TNFα specific antibodies

Details Selection of human TNFα specific antibodies Selection of human TNFα specific antibodies

2008-04-09

2010-10-05

Skelding, Zachary (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388230

Reexamination Certificate

active

07807168

ABSTRACT:
The invention relates to antibodies which bind to tumor necrosis factor α (TNFα) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFα-mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFα to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.

REFERENCES:
patent: 4444887 (1984-04-01), Hoffmann
patent: 4474893 (1984-10-01), Reading
patent: 4694778 (1987-09-01), Learn et al.
patent: 4714681 (1987-12-01), Reading
patent: 4716111 (1987-12-01), Osband et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5122464 (1992-06-01), Wilson et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5413923 (1995-05-01), Kucherlapati et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5573920 (1996-11-01), Randle
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5589369 (1996-12-01), Seidman et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5698426 (1997-12-01), Huse
patent: 5731168 (1998-03-01), Carter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5756096 (1998-05-01), Newman et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5837821 (1998-11-01), Wu
patent: 5859205 (1999-01-01), Adair et al.
patent: 5892019 (1999-04-01), Schlom et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6706477 (2004-03-01), Zauderer
patent: 6800442 (2004-10-01), Zauderer
patent: 6872518 (2005-03-01), Zauderer
patent: 7067251 (2006-06-01), Zauderer et al.
patent: 2002/0123057 (2002-09-01), Zauderer et al.
patent: 2002/0155537 (2002-10-01), Carter et al.
patent: 2006/0216293 (2006-09-01), Cuoto et al.
patent: 2007/0031440 (2007-02-01), Prior et al.
patent: WO 92/22324 (1992-12-01), None
patent: WO 00/44788 (2000-08-01), None
patent: WO 02/096948 (2002-12-01), None
patent: WO 2004/050683 (2004-06-01), None
patent: WO 2007/019064 (2007-02-01), None
Brown et al., J Immunol. May 1, 1996;156(9):3285-91.
Harlow et al., Antibodies, Cold Spring Harbor Press, pp. 23-35 (1988).
Eduardo Padlan, Mol Immunol. Feb. 1994;31(3):169-217.
Portolano et al., J Immunol. Feb. 1, 1993;150(3):880-7.
FDA Humira package insert, Sep. 26, 2003, pp. 1-18.
Hsia et al., APLAR Journal of Rheumatology, vol. 9, No. 2, Aug. 2006 , pp. 107-118.
Janeway et al., Immunobiology, 5th Ed., Garland Science, p. 98 (2001), pp. 102-103.
Baggiolini, M., et al., “Interleukin-8, a chemotactic and inflammatory cytokine,”FEBS Lett. 307:97-101, Elsevier Science Publishers (May 1992).
Better, M., et al., “Escherichia colisecretion of an active chimeric antibody fragment,”Science 240:1041-1043, American Association for the Advancement of Science (May 1988).
Bird, R.E., et al. “Single-chain antigen-binding proteins,”Science 242:423-442, American Association for the Advancement of Science (Apr. 1988).
Boder, E.T., et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,”Proc. Natl. Acad. Sci. U.S.A. 97:10701-05, National Academy of Sciences (Sep. 2000).
Daugherty, P.S., et al., “Flow cytometric screening of cell-based libraries,”J. Immunol. Methods 243:211-27, Elsevier Science Publishers (Sep. 2000).
Hanes, J., et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,”Nat. Biotechnol. 18:1287-92, Nature Publishing Group (Dec. 2000).
Hoogenboom, H.R. and Chames, P., “Natural and designer binding sites made by phage display technology,”Immunol. Today 21:371-78, Elsevier Science Publishers (Aug. 2000).
Huie, M.A., et al., “Antibodies to human fetal erythroid cells from a nonimmune phage antibody library,”Proc. Natl. Acad. Sci. U.S.A. 98:2682-87, National Academy of Sciences (Feb. 2001).
Huston, J.S., et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci. U.S.A. 85:5879-5883, National Academy of Sciences (Aug. 1988).
Irving, R.A., et al., “Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics,”J. Immunol. Methods 248:31-45, Elsevier Science Publishers (Feb. 2001).
Khabar, K.S., et al., “WEHI-13VAR: a stable and sensitive variant of WEHI 164 clone 13 fibrosarcoma for tumor necrosis factor bioassay,”Immunology Letters 46:107-110, Elsevier Science Publishers (May 1995).
Liu, B., et al., “Towards proteome-wide production of monoclonal antibody by phage display,”J. Mol. Biol. 315:1063-73, Elsevier Science Publishers (Feb. 2002).
Marks, J.D., et al., “By-passing immunization: building high affinity human antibodies by chain shuffling,”Biotechnology 10:779-783, Nature Publishing Group (Jul. 1992).
Morrison, S.L., et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,”Proc. Natl. Acad. Sci U.S.A.. 81:6851-55, National Academy of Sciences (Nov. 1984).
Mullinax, R.L., et al., “Expression of a heterodimeric Fab antibody protein in one cloning step,”BioTechniques 12:864-869, Informa Life Sciences Group (Jun. 1992).
Nagy, Z.A., et al., “Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells,”Nat. Med. 8:801-07, Nature Publishing Group (Aug. 2002).
Neuberger, M.S., et al., “Recombinant antibodies possessing novel effector functions,”Nature 312:604-08, Nature Publishing Group (Dec. 1984).
Pennica, D., et al., “Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin,”Nature 312:724-29, Nature Publishing Group (Jan. 1984).
Sawai, H., et al., “Direct production of the Fab fragment derived from the sperm immobilizing antibody using polymerase chain reaction and cDNA expression vectors,”Am J Reprod Immunol. 34:26-34, Blackwell Publishing (Jul. 1995).
Scallon, B., et al., “Binding and functional

Affiliated with

Also associated with

Rating

Selection of human TNFα specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selection of human TNFα specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selection of human TNFα specific antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4195749